Illumina, Inc. (NASDAQ:ILMN) received a $175.00 price target from research analysts at Deutsche Bank AG in a report released on Friday. The firm presently has a “hold” rating on the life sciences company’s stock. Deutsche Bank AG’s price target would indicate a potential upside of 0.38% from the company’s current price.

ILMN has been the topic of several other research reports. Vetr raised Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price target on the stock in a report on Monday, April 24th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a report on Thursday, April 13th. BidaskClub cut Illumina from a “hold” rating to a “sell” rating in a report on Wednesday, July 5th. Cantor Fitzgerald raised their price target on Illumina from $155.00 to $170.00 and gave the company a “neutral” rating in a report on Wednesday, April 26th. Finally, Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $187.00 price target (up previously from $170.00) on shares of Illumina in a report on Friday, April 14th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $167.02.

Illumina (NASDAQ ILMN) traded up 0.14% on Friday, reaching $174.57. The company had a trading volume of 220,198 shares. The stock has a market capitalization of $25.49 billion, a P/E ratio of 35.33 and a beta of 0.84. The stock’s 50-day moving average price is $174.72 and its 200-day moving average price is $171.38. Illumina has a 12-month low of $119.37 and a 12-month high of $189.48.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The firm had revenue of $598 million for the quarter, compared to analysts’ expectations of $590.51 million. During the same quarter last year, the firm posted $0.71 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. On average, equities research analysts anticipate that Illumina will post $3.63 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/07/28/illumina-inc-ilmn-pt-set-at-175-00-by-deutsche-bank-ag.html.

In other news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $184.14, for a total value of $3,682,800.00. Following the sale, the director now directly owns 539,176 shares in the company, valued at approximately $99,283,868.64. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Charles Dadswell sold 145 shares of Illumina stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $184.75, for a total value of $26,788.75. Following the completion of the sale, the senior vice president now owns 10,791 shares in the company, valued at $1,993,637.25. The disclosure for this sale can be found here. Over the last quarter, insiders sold 125,248 shares of company stock worth $22,281,673. Corporate insiders own 1.60% of the company’s stock.

Several large investors have recently modified their holdings of ILMN. DnB Asset Management AS raised its stake in shares of Illumina by 18.3% in the first quarter. DnB Asset Management AS now owns 16,089 shares of the life sciences company’s stock worth $2,745,000 after buying an additional 2,490 shares in the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of Illumina during the first quarter worth $939,000. Eastern Bank acquired a new stake in shares of Illumina during the first quarter worth $256,000. Bank of Montreal Can raised its stake in shares of Illumina by 61.0% in the first quarter. Bank of Montreal Can now owns 113,182 shares of the life sciences company’s stock worth $19,314,000 after buying an additional 42,876 shares in the last quarter. Finally, National Pension Service raised its stake in shares of Illumina by 3.7% in the first quarter. National Pension Service now owns 122,352 shares of the life sciences company’s stock worth $21,186,000 after buying an additional 4,331 shares in the last quarter. Hedge funds and other institutional investors own 93.75% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.